Speaker at Pharmaceutics and Drug Delivery Systems 2022 - Mohammad H. Alyami
Najran University, Saudi Arabia
Title : Novel Fluticasone Propionate and Salmeterol Fixed-Dose Combination Nano-Encapsulated Particles Using Polyamide Based on L-Lysine


 The aim of this study is to develop a dry powder inhaler (DPI) of an inhalable potent fixed-dose combination (FDC) for the management of asthma. Herein, a one-step approach is presented for the synthesis of nanoaggregates made from a biocompatible and biodegradable polyamide employing (fluticasone propionate (FP) and salmeterol xinafoate (SAL)). The nanoaggregates were synthesized using interfacial polycondensation that produced nanocapsules with an average particle size of 226.7 _ 35.3 nm and zeta potential of ????30.6 _ 4.2 mV. The FDC nanocapsules displayed 88.5% and 98.5% of the emitted dose for FP and SAL, respectively. The fine particle fraction of the nominated dose was superior to the marketed product (Seretide Diskus®, Brentford, United Kingdom). The in-vitro release study showed an extended drug release profile.


Dr Mohammad H. Alyami graduated as BSc at Pharmacy from Saudi Arabia – Abha and few years later completed MSc (Birmingham- UK) 2014, & Ph.D. (Birmingham- UK) 2020 in Pharmaceutical Sciences & Drug Delivery.  I’m working as Assistant Professor of Pharmaceutics and Drug Delivery, at Najran University- Pharmacy Faculty. I'm committed to my own and public research with a number of national and international colleagues especially in the development of novel techniques for oral, topical and pulmonary drug delivery.